


# **Antibody-based therapies may be effective in fight against influenza B**


August 4 2023

---


**A** B/Yamagata infected patients  
Mean ordinal outcomes




**B** A/H1N1 infected patients  
Mean ordinal outcomes




**C** B/Yamagata infected patients  
Ordinal outcome distribution



**D** A/H1N1 infected patients  
Ordinal outcome distribution



**E** B/Yamagata and A/H1N1 infected subjects  
Proportional odds analysis of outcome



Treatment with Flu-IVIG improves the odds of a more favorable clinical outcome in patients hospitalized with severe B/Yamagata influenza but not A/H1N1 influenza. Mean ordinal outcomes (A and B) and ordinal outcome distributions (C and D) on day 3 (d3), d5, and d7 after infusion are shown for the Flu-IVIG– and placebo-infused patients infected with severe B/Yamagata influenza (Flu-IVIG n = 33 and placebo n = 29; A and C) and A/H1N1 influenza (Flu-IVIG n = 24 and placebo n = 26; B and D). The Flu-IVIG/placebo odds ratios (ORs) with 95% confidence intervals for the B/Yamagata- and A/H1N1-infected participants were calculated on d3, d5, and d7 after infusion (E). A proportional odds model with adjustment for the patient’s baseline clinical status was used to compare the Flu-IVIG– and placebo-treated groups. \*P

Citation: Antibody-based therapies may be effective in fight against influenza B (2023, August 4) retrieved 28 April 2024 from <https://medicalxpress.com/news/2023-08-antibody-based-therapies-effective-influenza.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.